Beactica has expanded its collaboration with Boehringer Ingelheim under which Beactica will use its fragment-based platform to identify novel and selective hits against oncology-relevant kinases of interest to Boehringer. Financial terms were not disclosed.   “We are pleased to expand our work with Boehringer Ingelheim and look forward to further supporting them in their discovery of innovative, new medicines for the treatment of cancer,” said Beactica chief executive officer, Dr. Pe...